Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The overarching goal of this FOA is to add informatics capabilities to the Common Fund program, ?Illuminating the Druggable Genome? IDG; The IDG consortium's purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC).
The purpose of this specific FOA is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the KMC as well as the broader IDG Consortium in the following ways: (1) by developing and deploying tools to enhance the community?s ability to process, analyze, and visualize IDG data, (2) to prioritize new data resources and methods to be incorporated into Pharos that will strengthen predictions about physiological and disease associations around the understudied proteins, and (3) by developing methods to prioritize understudied IDG families (non-olfactory GPCRs, protein kinases, and ion channels) for deeper study using experimental assays both within the IDG pipeline or by the larger community.


  • Letter of Intent Due Date(s): June 9, 2018
  • Application Due Date(s): July 9, 2018

RFA-RM-18-011 Expiration Date July 10, 2018

Agency Website



Amount Description

Application budgets are limited to $300,000 in total direct costs (excluding subcontract F&A) per year and need to reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is 2 years.

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

July 9, 2018